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Abstract
Haemodiafiltration (HDF) is the blood purification therapy
ofchoiceforthosewhowantsignificantremovalofuraemic
solutes beyond the traditional range of small molecules.
Combiningdiffusiveandconvectivesolutetransport,aHDF
treatment comprises the largest number of variables among
blood purification therapies, and it is important to under-
stand how they interact in order to optimize the therapy.
This review discusses the parameters that determine the
efficiency of HDF and how they can be controlled in the
different forms of HDF and ‘HDF-like’ therapies practised
today. The key to safe and effective HDF therapy is to have
accesstolargevolumesofhigh-qualityfluids.Startingwith
ultrapuredialysisfluid,on-linepreparationofasterile,non-
pyrogenicsubstitutionsolutioncanbemadeanintegralpart
of the treatment, and we describe the necessary conditions
forthis.On-lineHDFcanprovidethelargestremovalofthe
widest range of solutes among available dialysis therapies,
andthepotentialclinicalbenefitsofthisarewithinpractical
reach for the increasing number of patients dialysed with
high-flux membranes and ultrapure dialysis fluid.
Keywords: convection; haemodiafiltration; on-line fluid preparation;
postdilution; predilution
Introduction
Data from two large, randomized, controlled studies, in-
vestigating whether the outcome of long-term dialysis can
be improved by using high-flux rather than low-flux dialy-
sis membranes, have shown significant benefits for certain
high-risk patients and certain causes of death from the in-
creased removal of larger solutes achieved with high-flux
filters [1–4]. Extrapolating from these data leads to an as-
sumptionthatiftheremovalofsuchsolutescouldbefurther
increased, as in certain forms of haemodiafiltration (HDF),
the benefit might be extended to more patients. In com-
parison with other dialysis modalities, HDF has also been
shown to provide superior removal of some protein-bound
uraemic solutes [5]. Although outcome evidence from ran-
domized controlled trials is still missing, superior survival
is reported from observational studies and clinical benefits
have been documented in numerous studies, all for patients
treated with HDF compared to conventional dialysis [6–
8]. As a consequence, the interest in applying this form of
bloodpurificationisincreasingworldwide.Arecentsurvey
among >6000 nephrology professionals showed that 80%
consider dialysis with a high-flux membrane superior to
using a low-flux membrane, and among them ∼50% prefer
a convective therapy [9].
High-flux membranes are designed for high fluid flows
andconvective transport,andwhenappliedinmainlydiffu-
sive modes with limited convection, such as haemodialysis
(HD), their full potential is not utilized. When convective
transport is consciously added to the therapy, as in HDF,
the prescription needs to be carefully considered with re-
gard to the different parameters to give the full benefit of
the HDF therapy. In fact, a HDF treatment comprises the
largest number of treatment variables among blood purifi-
cation therapies, and it is important to understand how they
interact with each other in order to optimize the therapy
[10]. The interest in applying HDF therapy has resulted in a
flora of modalities that differ mainly in the amount of con-
vection applied, the way it can be controlled and the mode
of fluid administration. To date, there is no overview of all
these different modes of HDF. We therefore felt the need to
review the basic parameters that determine the efficiency
ofHDFanddiscusshowtheycanbecontrolledintheforms
of HDF practised today. The key to effective HDF therapy
istohaveaccesstohigh-qualityfluids,andon-lineprepara-
tion of sterile, non-pyrogenic substitution solution has met
with regulatory obstacles in some countries and limited the
adoption of therapy. We will discuss the safety of on-line
fluidpreparationwithreferencetotherecentlyreleasedISO
standard, an important document which for the first time,
in a multinationally recognized standard, identifies and de-
fines on-line ultrafiltration as a method to prepare a sterile
solution [11].
Parameters controlling the efficiency of
haemodiafiltration
Introduction
HDF is a form of blood purification that can be used for
treatment of acute as well as chronic renal failure. HDF
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utilizes a combination of diffusive and convective solute
transport through a highly permeable dialysis membrane.
The diffusive transport requires the presence of dialy-
sis fluid flowing through the dialyser counter-currently to
blood. The convective transport requires ultrafiltration of
fluidtoan extent that exceeds the desired weight loss.Fluid
balance is maintained by infusion of a replacement fluid,
which can be administered before the filter (predilution),
after the filter (postdilution) or inside the filter. The re-
placement fluid, also referred to as substitution fluid, is
mixed with the blood and should therefore be sterile and
non-pyrogenic with a composition similar to plasma water.
This fluid can be provided in industrially prepared, auto-
claved,plasticbagsorcanbegeneratedasanintegralpartof
the treatment, either externally through quality-controlled,
stepwise ultrafiltration or internally through backfiltration
of dialysate [10].
Diffusion [12]
In HDF, as well as in HD, the driving force for diffusive
transport across the membrane is the difference in con-
centration between the blood and the dialysis fluid for
each particular solute. The rate of diffusion depends on
molecular size and resistance to flow. This resistance is
mainly represented by the membrane, but the distance
in the blood path, i.e. the diameter of the hollow fi-
bre, also plays a role. Small molecules are favoured be-
cause the rate of diffusion is inversely proportional to
the cubic root of the molecular weight. All characteris-
tics of a dialyser for diffusive transport are expressed by
K0A, the mass transfer area coefficient, showing clearance
at infinite flow rates (K0) and incorporating the surface
area (A).
To maximize diffusive transport in clinical practice,
flow rates for blood and dialysis fluid should be high to
maintain a large concentration gradient. The blood flow
should be as high as the access conditions permit. An
old rule of thumb says to aim for a 1:2 relationship be-
tween blood flow and dialysis fluid flow, but optimal con-
ditions can be obtained with modern dialysers at somewhat
lower dialysis fluid flow rates [13]. Among the three con-
trolling parameters—blood flow rate, dialysis fluid flow
rate and dialyzer surface area—the patient-related para-
meter, i.e. blood flow, should be the determinant of the
others.
Low-flux HD, frequently referred to as conventional
HD, is a good example of a diffusive therapy. Low-flux
membranes are characterized by high diffusive perme-
ability, which means that small solutes move easily back
and forth across the membrane along their respective
concentration gradient. However, because neither transport
of medium-sized and large solutes nor a high water flow
can be achieved with low-flux membranes, the convective
transport is reduced to negligible amounts. Increased effi-
ciency, achieved through increased flow rates for blood and
dialysis fluid and dialysers with a larger surface area, can
be seen as increased removal of small solutes like urea and
creatinine, while it has little effect on larger solutes such as
ß2-microglobulin [1].
Fig. 1. Sieving curves for low-flux and high-flux dialysis membranes and
human glomerular basement membrane. The molecular size for which the
sieving coefficient = 0.1 is the cut-off of the membrane.
Convection [12]
Convective transport in dialysis consists of solutes pas-
sively following a fluid flow, ultrafiltration, across a highly
permeable membrane (solvent drag). The hydraulic perme-
abilityofthemembraneandthepressuregradientacrossthe
membrane, referred to as transmembrane pressure (TMP),
determine the rate of ultrafiltration. The membrane perme-
ability to solutes, sieving properties, is determined by the
size of the pores in the membrane and sets the limit for
which solutes can be dragged across the membrane by the
fluid flow. The sieving coefficient (S) of a particular mem-
brane for a specific solute, a value between 0 and 1, is the
ratio between the solute concentration in the filtrate and
the solute concentration in the blood, in the absence of ad-
sorption. The sieving curve for a membrane shows how the
sieving changes with increasing molecular weight, which
is assumed to reflect the size (Figure 1). The shape of the
curve where S falls from 1 to 0 indicates the distribution
of pore sizes, and the molecular weight where S = 0.1 is
referred to as the cut-off. Membranes with a sieving curve
similar to that of the glomerular basement membrane, i.e.
withasteeplyfallingprofileandacut-offjustbelowthesize
of albumin, are ideal for HDF. Depending on the physico-
chemical attraction between the blood components and the
membrane polymer, the sieving properties may change at
exposure to blood. It is therefore important to apply clin-
ically relevant conditions when comparing the therapeutic
utility of different membranes. For all solutes with S = 1,
therateofconvectiveremovalequalstheultrafiltrationrate.
If the ultrafiltration rate also equals the convective clear-
ance from blood. The amount of solute removed depends
ontheconcentrationintheincomingfluid,i.e.theundiluted
or diluted blood. For solutes with S < 1, the concentration
needs to be multiplied with the relevant S value.
Haemofiltration (HF) is a therapy in which solute re-
moval relies entirely on convection. When applied in the
traditional postdilution mode, using high blood flow rates
and large ultrafiltration volumes, this therapy can provide
adequate removal of small molecules and high removal
of middle and large molecules [14]. When used in the
predilution mode the clearance of small as well as mid-
dle molecules can be significantly increased, provided the
infusion flow rate matches the blood flow rate. This has
enabled clinical application in average size patients with10 I. Ledebo and P. J. Blankestijn
Fig. 2. Clearance in postdilution HDF for urea (MW = 60), vitamin
B12 (MW = 1 355) and inulin (MW = 5 000) illustrating the impact of
increasing convection (dark areas) on diffusion (light areas) at a blood
flow rate of 300 ml/min and increasing ultrafiltration rate. Reprinted from
[14] with permission.
normal blood flow capacity [15]. To increase the efficiency
of HF, a higher ultrafiltration flow rate must be generated
and this requires a higher blood flow rate and sometimes
alsoalargermembranesurfacearea.Theresultwillbeseen
as increased clearance of a wide range of solutes.
Interaction between diffusion and convection
In HDF, diffusion and convection occur simultaneously,
but the effects are not simply additive because they inter-
fere with each other. Diffusion reduces the concentration of
small solutes, leaving less for convective removal, and con-
vectionreducesthebloodflowandthusthedrivingforcefor
diffusion. When on-line prepared fluid is used, convection
also reduces the dialysis fluid flow as this fluid serves as
the source of substitution fluid. Thus, convection has lim-
ited value for the clearance of small solutes, while it is of
progressive importance for solutes of increasing molecular
weight (Figure 2) [14]. Mathematical models suggest that
40–50% of the ultrafiltration rates represent the convective
clearance that can be added to pure diffusion, when the
transport processes are combined [16].
The balance between diffusion and convection can be
adjusted through the controlling parameters. Convection is
usually prioritized, and this is achieved by aiming for max-
imum ultrafiltration. A realistic filtration fraction without
excessive build-up of pressure may be 50% of the plasma
volume or 25–35% of the blood volume. However, finding
the optimal UF rate requires an experienced nurse, and in
reality, many HDF treatments are operated under subopti-
mal conditions to avoid TMP alarms and save nursing time
[17].Aconvenientapproachistoletthemachinecontrolthe
UF rate by selecting and adjusting the TMP automatically.
This has been found to result in higher filtration fraction
and efficiency [18].
Dilution
Problems with low ultrafiltration volumes and high TMP
values can be solved by diluting the blood before the filtra-
tion. However, both diffusion and convection are affected
by the dilution, which means that ultrafiltration is facili-
tated at the cost of efficiency. Diluted blood means lower
concentrationofuraemicsoluteswhichimpactsdiffusionas
well as convection. The lower solute concentration means
that the driving force for diffusive transport is reduced and
thedilutedultrafiltratecontainslesssolutes.Treatmentses-
sions with predilution HDF require approximately twice as
much infusion fluid to provide a dose comparable to a post-
dilution HDF session under the same conditions of blood
flow, filter size and treatment time [19]. With access to
on-line prepared fluid, the volume requirement has neither
practical nor economical limits, but there may be concerns
about exposing patients to very large fluid volumes.
In postdilution modes, the volume of ultrafiltration is
equal to that of convection and it gives a convenient mea-
sure of the dose. When the fluid is administered in the
predilution mode, quantification becomes more difficult
because the ultrafiltrate is now diluted. With externally
added replacement fluid in the predilution mode, the ul-
trafiltration volume can be corrected for the dilution. The
effective convection volume is calculated by multiplying
the actual volume of diluted ultrafiltrate with the degree
of dilution (Qb/(Qb+Qinf)). In all modes involving some
form of uncontrolled dilution, whether as a combination of
pre- and postdilution or administered inside the filter, the
volume of ultrafiltrate is of little value for quantification,
and the efficiency of the convective removal can only be
assessed by standard clearance or removal measurements.
In special cases, predilution may be the only possibility
to provide an adequate HDF treatment. One such instance
ispatientswithveryhighhaematocritorbloodcomposition
that limits the filtration capacity. Another case is patients
with low blood flow rates, e.g. paediatric patients for whom
HDF has proven to be of significant benefit [20]. A com-
promise may be to use a limited amount of predilution,
sufficient to avoid problems with filtration and elevated
pressures, and combine it with postdilution, but finding the
optimal distribution between the flow rates before and after
the filter may be difficult. Automatic shifting between pre-
and postdilution by the machine in response to pressure
changes has been proposed by Pedrini and demonstrated
to give a satisfactory result [21]. In spite of the drawbacks
with predilution, it is frequently used to facilitate the man-
agement of the treatment, and users may be unaware of the
loss of efficiency.
Conclusion
Comparing the clearance that can be obtained by the four
modes of dialysis therapy—low-flux HD, high-flux HD,
HDFandHF—showsthatifwewantsignificantremovalof
uraemic solutes in the middle and large molecular weight
range, we need to maximize the convective transport by
applying HDF or even HF [22]. If in addition we want
to optimize the small solute removal, HDF is the choice.
Starting from the blood flow that can be provided by the
patient access, the ultrafiltration should be maximized with
respect to blood composition and pressures. This can today
beachievedwiththesupportofbiofeedbackprogrammesin
the dialysis equipment [18,21]. Operating in the postdilu-
tion mode is most effective, regarding the delivered dose as
well as the quantification of it, and should be preferred
whenever possible. Concerns about removing beneficial
solutes and creating deficits by excess dialysis with highlyHaemodiafiltration 11
Fig. 3. Flow diagrams for different forms of haemodiafiltration (HDF)
at typical operating conditions (blood flow rate 300 ml/min, dialysis fluid
flow rate 500 ml/min and weight loss 10 ml/min) showing possible con-
vective removal.
efficient blood purification have been voiced, but the liter-
ature contains no evidence of this.
Different forms of haemodiafiltration
Introduction
Theterm‘haemodiafiltration’appearedfirstinthenephrol-
ogy literature in 1975 to describe the treatment form that
was later renamed ‘haemofiltration’ [23]. Today, HDF is
used as a general term for treatment modes in which diffu-
sionandconvectionareconsciouslycombined.Theoriginal
forms of HDF—classical HDF and on-line HDF—belong
to this group and are additionally characterized by exter-
nal infusion of controlled amounts of substitution solution
(Figure 3). Some treatment modes set up as HD may also
comprise considerable solute removal through convection.
They may be referred to as HDF or HD, and they are char-
acterized by uncontrolled ultrafiltration and uncontrolled
generation of the substitution solution, the latter provided
by backfiltration of dialysate inside the filter. Among such
forms, we find push–pull HDF, double high-flux HDF and
high-flux HD. When comparing the clinical outcome of
different studies, it is important to realize that there may
be wide differences among treatment modes referred to as
HDF, and great similarities between some forms of HDF
and some forms of HD.
Classical haemodiafiltration
This therapy was introduced in 1978 as an effective alter-
native to HD and HF [24]. Classical HDF is characterized
by using external substitution fluid provided as a sterile
solution, autoclaved in plastic bags (Figure 3). It can be
performed on standard HD machines fitted with an extra
pump and a weighing device for fluid balancing. For prac-
tical and economical reasons, the volume of the infusion
solution is limited and 8–10 l of fluid is most commonly
used. In the 1980s, the infusion solution contained lac-
tate as the buffer source; however, with growing evidence
of the benefits of bicarbonate as buffer in HD fluids, phar-
maceutical preparations ofbicarbonate-containing infusion
solutionforHDFstartedtoappearandresultedinenhanced
correction of acidosis [25]. Today, the use of classical HDF
is limited to countries with special reimbursement for this
treatment mode and physicians wanting specialized infu-
sion solutions. An example of this is acetate-free biofil-
tration (AFB), mainly used in Italy, in which the dialysis
fluid is buffer-free and an isotonic bicarbonate solution is
infused in postdilution mode [26].
On-line haemodiafiltration
This therapy was first described in 1985, when Canaud re-
ported his experience of using a prototype, multipurpose
machine, which could perform HD, HDF and HF and could
also prepare the substitution solution continuously during
the treatment [27]. The principles of on-line preparation
of the sterile, non-pyrogenic substitution solution are de-
scribed below. With the development of easy-to-use equip-
mentforon-lineHDF,theuseofthistherapyhasspreadand
it has largely replaced classical HDF. It is estimated that
∼10% of dialysis patients in Western Europe are treated
with on-line HDF.
The limiting factors to further application have mainly
been regulations and restrictions from authorities on the
use of on-line prepared substitution fluid [28]. Continu-
ous sterilization by ultrafiltration and immediate use, i.e.
the essence of on-line preparation, is not considered in
the Pharmacopoeia as a sterilization method [29,30]. Fur-
thermore, the preparation of a drug (substitution solution)
from a device (dialysis fluid) using another device (ultrafil-
ter) is a process that falls outside this rulebook. Therefore,
in the countries where on-line preparation has been ac-
cepted by the regulatory authorities, e.g. France, Sweden
and the Netherlands, there are detailed instructions about
conditions to be fulfilled and procedures for testing to be
followed.Inothercountries,thishasbeenlefttotheindivid-
ual units and practitioners. However, the new International
Standard for fluids for dialysis should pave the way for a
more pragmatic, yet safe, view of how stepwise, controlled
filtration can be used to prepare sterile, non-pyrogenic
fluids [11].
When referring to on-line HDF as a concept, one em-
phasizes the fact that the substitution solution is prepared
as an integral part of the treatment in practically unlimited
volumes with individualized composition. To characterize
thetreatmentfurtheroneshouldalsostatehowthesubstitu-
tion solution is administered, because this may have major
impact on the efficiency. While predilution is true dilution
oftheblood,postdilutionisactuallyreplacementofultrafil-
tered volume. Mixed dilution is a combination of pre- and
postdilutionandsoismid-dilution,amethodthatrequiresa
specialtypeoffilterwherethefluidcanbeinfusedbetween
two separate fibre bundles [31].
Haemodiafiltration with internal fluid substitution
The promising benefits of HDF therapy and the practi-
cal and economical problems connected with using infu-
sion solution in bags, combined with the regulatory re-
strictions around on-line fluid preparation, have stimulated
creative minds to seek other ways to apply the therapy.12 I. Ledebo and P. J. Blankestijn
Common to these versions of HDF is that backfiltered
dialysate is used as substitution solution and fluid balance
is maintained by the volume control function of the HD
machine. The amount of ultrafiltration usually cannot be
controlled, but becomes a consequence of the treatment
conditions.
Push-pull HDF. Shinzato described push–pull HDF as
infusion-free HDF already in 1982 [32]. He had cre-
ated a system where alternating pressure pulses pull and
push fluid across the membrane, resulting in fluid re-
moval and fluid replacement taking place in rapid se-
quences inside the filter. The efficiency of this form of
HDF shows that the added convective transport contributes
to enhanced clearance of middle and large molecules, how-
ever, not to the extent that can be achieved with on-line
HDF.
Double high-flux HDF. This form of HDF was created in
LosAngeles,andtheclinicalresultusingthesuper-efficient
treatmentwasfirstreportedin1984[33].Twolargefiltersin
series are used and the pressure between them is adjusted
so that fluid removal from blood takes place in the first
filter and fluid replacement in the second. High blood flow
rates, in excess of 500 ml/min, are required to achieve the
desiredeffect.Diffusionoccursinbothfilters,butisgreatly
affected by the fluxes of fluid across the membrane. As in
push–pull HDF, the substitution fluid consists of dialysate
backfiltered across the membrane in the second dialyser.
The clearances that can be achieved for a wide range of
solutes with this form of HDF are impressive and reflect
the large surface area of the filters and the high flow rates
of blood and fluid.
High-flux dialysis. The final form of infusion-free HDF
is simply high-flux dialysis, i.e. HD in which a high-flux
membrane is used and the weight loss is controlled by stan-
dard HD equipment (Figure 3). The hydraulic permeability
of all high-flux filters (UF coefficient > 20 ml/h, mmHg,
m2) invariably leads to ultrafiltration rates in excess of the
desired fluid removal rate, and the volume control function
of the dialysis machine automatically compensates for the
excess by adjusting the fluid pressure and forcing fluid in
the opposite direction. This is referred to as backfiltration
and it takes place in all forms of high-flux dialysis, unless
the desired weight loss is exceptionally large. As in the
other forms of infusion-free HDF, the amount of ultrafil-
tration and thus convective transport cannot be controlled,
but it can be affected through manipulation of the pres-
sures over the filter. The more resistance the blood meets
on its way through the hollow fibres, the higher is the in-
let pressure, the larger the pressure drop and the greater
the ultrafiltration. Thus, high blood flow rates, small fibre
diameters and long filters will increase the fluid fluxes
across the membrane inside the dialyser and thus the con-
vection. The internal filtration in high-flux HD can amount
to 30–40 ml/min under favourable conditions and the con-
vective transport can thus be comparable to classic or low-
volume HDF [34].
Comparing different forms of haemodiafiltration
Using pressure manipulations and backfiltration of
dialysatemayseemlikeasimpleandelegantwaytoachieve
additional convective clearance, but there are a number
of caveats connected with this practice. The most serious
concern is the microbiological quality of the fluid that is
infused into patient blood. Compared to on-line prepara-
tion of sterile and non-pyrogenic substitution solution, a
validated and highly controlled process, safe backfiltra-
tion relies on the dialysate being at least ultrapure (see
below) and the dialysis membrane being able to func-
tion as a sterilizing filter. These requirements may be ful-
filled in experienced clinics practising push–pull HDF and
double high-flux dialysis, but are probably overlooked by
the majority of clinics performing high-flux dialysis. Al-
though few obvious clinical symptoms are directly associ-
ated with this practice, microinflammation manifested by
elevated CRP levels may be a consequence [35]. Another
risk connected with the high pre-filter pressures required
to increase ultrafiltration in the arterial part of the filter
is albumin leakage and mechanical damage to the blood
cells [36].
Other drawbacks when performing high-flux HD in lieu
of HDF relate to the efficiency of the therapy, which is
obviously affected by the inability to determine the ul-
trafiltration. The ultrafiltration rate can neither be con-
trolled nor measured, and the same applies to the con-
vective removal. The efficiency is also reduced by the
fact that dialysis fluid already exposed to uraemic blood
is used for sustitution, rather than unused fluid. Although
infused in the venous end of the filter, the quality cannot
be compared to that of the substitution solution intended
for the purpose. Finally, the efficiency suffers from com-
petition between the three ongoing processes—diffusion,
ultrafiltration and backfiltration—with flux in differ-
ent directions taking place simultaneously across the
same membrane surface. The dialyser now serves the
purpose of fluid purification in addition to blood
purification.
Conclusion
High-flux dialysis, which can be considered as a low-
efficiency version of HDF, is today used for two-thirds of
HD patients in the world [37], giving them the benefit of
some convective clearance, but at the same time exposing
them to the risk of bacterial products reaching the blood
and inducing microinflammation. The convection volume
in contemporary high-flux dialysis can be almost as high
as in classical HDF, which is important to realize when
discussing the outcome of different therapies. Compared
to high-flux dialysis and classical HDF, on-line HDF can
provide significantly larger convection volumes that can
be reached without practical or economical constraints and
with a high safety level for the patient. On-line HDF is thus
the most efficient way of performing HDF. With access
to on-line prepared fluids, the substitution solution can be
added in pre-, mid-, mixed- or post-dilution mode. Diluting
the blood before the filtration may facilitate the treatment,
but it also dilutes the ultrafiltration and thus the efficiency.Haemodiafiltration 13
Fig. 4. Process steps in the preparation of fluids for dialysis starting with tap water and resulting in sterile, non-pyrogenic substitution fluid for on-line,
convective therapies. (RO = reverse osmosis, CFU = colony-forming units, EU = endotoxin units, SAL = sterility assurance level).
Fluids for haemodiafiltration
Introduction
Dialysispatientsareexposedtolargevolumesoffluid,only
separated from their blood by a semipermeable membrane
and sometimes even mixed with the blood. Standards and
recommendations for the chemical quality of water and
dialysis fluid should be followed whether the fluid is used
for HD or HDF [38]. With respect to the microbiological
quality, the fluids used in dialysis can be divided into three
levels—standard, ultrapure and sterile—and all three are
of relevance to HDF (Figure 4) [11]. The current maxi-
mum levels of microbiological contaminants, measured as
colony-forming units (CFU) and endotoxin units (EU), in
the different fluids for dialysis are shown below [11]. All
values refer to fluids tested with sensitive methods, pre-
viously described and recommended [39] and now also
confirmed by the new ISO standard [11].
– Standard quality dialysis fluid should have a bacterial
count <100 CFU/ml and an endotoxin level <0.50
EU/ml.
– Ultrapure quality dialysis fluid should have a bacte-
rial count <0.1 CFU/ml and an endotoxin level <0.03
EU/ml.
– Sterilequalityfluidcannotbedefinedbyacertainbac-
terial content, because it can not be tested as such. The
volume used for each application should be free from
viable bacteria with a sterility assurance level (SAL)
of 6 magnitudes, i.e. 1000000 times. It should also be
non-pyrogenic, which is defined as an endotoxin level
<0.03 EU/ml.
Standard quality dialysis fluid
Water for dialysis is prepared from tap water by passage
through a series of filters to remove microparticles, organic
and inorganic matter. Reverse osmosis is used as the final
step and the result should be water that fulfils the recom-
mended quality demands, chemically as well as microbio-
logically [11,38]. Standard quality water for dialysis (<100
CFU/ml and <0.25 EU/ml) can serve as the base for the
preparationofallotherfluidsfordialysis(Figure4).Should
the treated water not meet this target, it should not be used
forany formofdialysis.Themicrobiological qualityofwa-
ter can be safeguarded by one step of ultrafiltration before
introductionintothedialysismachineandmixingwithcon-
centrates. In the preparation of dialysis fluid for standard
HD, the microbiological quality of the water should not
be allowed to deteriorate significantly, because the same
upper limit for the bacterial content is valid for dialysis
fluid as for water. In practice this means that the entire flow
path, from the reverse osmosis equipment to the dialyser,
should be frequently disinfected and the microbiological
qualityoftheconcentratesshouldbehigh.Specialattention
must be paid to the bicarbonate concentrate, which is prone
to bacterial proliferation. The minimum requirement that
can be placed on dialysis fluid today is to be of standard
quality,butareasonablerecommendationistousethisfluid
qualityonlyinlow-fluxHDwithsyntheticmembranes[40].
Backdiffusion of bacterial products has been documented
with low-flux cellulosic membranes and backfiltration of
dialysate into the blood may occur in all HD treatments
with high-flux membranes [41]. Standard-quality dialysis
fluid should therefore not be used in any form of HDF ther-
apy,whetherthesubstitutionfluidisexternallyorinternally
infused [42].
Ultrapure dialysis fluid
One step of controlled ultrafiltration converts standard
quality dialysis fluid into ultrapure dialysis fluid and it
should take place as close to the dialyser inlet as possi-
ble to avoid further contamination of the fluid [43]. Most
modern dialysis machines can be equipped with ultrafilters
integrated in the fluid flow path. Ultrafilters work by reten-
tionthroughsizeexclusionaswellasbyadsorptionthrough
hydrophobic binding. They should be labelled for the pur-
pose and validated to have a logarithmic reduction capacity
for bacteria of at least 7 magnitudes and for endotoxin of
3–4 magnitudes. They should also have a declared resis-
tance to multiple disinfection cycles [10]. The integrity of
the membrane is guaranteed through pressure tests of indi-
vidual filters in production [28]. Regular dialysers should
not be used as ultrafilters, although they may appear to14 I. Ledebo and P. J. Blankestijn
contain similar membranes, because polymer blends may
lead to different adsorptive properties [44]. To date, there
are no randomized controlled studies comparing the effect
of ultrapure versus standard quality dialysis fluid on out-
come. However, numerous clinical studies show significant
improvement of inflammatory parameters when patients
are switched from standard fluid to ultrapure fluid [45,46].
Basedonthesefindings,theEuropeanBestPracticeGuide-
linesaswellastheguidelinesfromtheJapaneseSocietyfor
Dialysis Therapy recommend the use of ultrapure dialysis
fluid for all forms of dialysis [47,48].
Sterile fluid, prepared in bags
Substitution fluid for convective therapies is regarded as a
drug, or an infusion solution, by the European as well as
the US Pharmacopoiea [29,30]. They both say that the fluid
must be sterile and should contain <0.25 EU/ml. Consider-
ing the fluid volumes infused in modern versions of HDF,
4–6 l/h, the maximum recommended endotoxin exposure
for healthy individuals (5 EU/kg body weight and hour)
could be exceeded already at moderate infusion rates and
body weights using this fluid [49]. It is therefore important
that the substitution solution for HDF is of considerably
higher microbiological quality than stipulated by the au-
thorities.
Sterile fluid, on-line prepared
With access to ultrapure dialysis fluid, it takes one addi-
tional step of controlled ultrafiltration to reach a quality
level that can be described as sterile and non-pyrogenic
(Figure4).Toguaranteetheendresult,twobasicconditions
mustbefulfilled:(1)thedialysisfluidmustbeultrapurebe-
forethefinalfiltrationand(2)thefinalultrafiltermusthave
the capacity to function as a sterilizing filter. Each clinic
practicing on-line HDF must have a validated process for
theirentirechainoffluidpreparationfromtheincomingwa-
ter to the final ultrafilter. A recent publication describes the
importantstepsandthequalitylevelachievedandillustrates
the value of the quality control process [50]. When setting
up such a process correct microbiological sampling must
be frequently performed and the frequency can be reduced
only when the result is satisfactory and reproducible [28].
Because sterility cannot be proven by testing, it is the
quality of the fluid before the final filter and the function-
ality of this filter that together determine whether the final
fluid can be referred to as sterile and non-pyrogenic. The
safety philosophy among manufacturers of on-line systems
differs on this issue. Some use a sterile, single-use filter
for the final filtration step and regard this as vital, while
others use a disinfected, multiple-use filter and refer to the
final filtration step as redundant. This reflects a difference
in the interpretation of the sterility concept by the respec-
tive manufacturers of equipment. The possible difference
in fluid quality can be translated into a question of risk
management. Still, the safety margin built into approved
on-line systems, when managed according to the operating
instructions, is several magnitudes and the experience from
thousands of treatments has shown us that the procedure
can be considered safe for the patient [50–52].
The literature, unfortunately, contains confusing termi-
nology and statements regarding on-line prepared fluids.
The substitution fluid, although universally regarded as
sterile, is sometimes referred to as ‘ultrapure’. If it were
ultrapure, it would mean infusion of up to 400–600 CFU/h
directly into the blood, based on the current definition of
ultrapure (<0.1 CFU/ml) and common versions of on-line
HDFwith4–6linfusion/h.Anothermisnomeroccurswhen
ultrapure dialysis fluid is referred to as ‘sterile’. The back-
ground to this may be that no growth is found when small
samples of the fluid are tested. An ultrapure fluid would
produce at the most one bacterial colony on one agar plate
for every 10 plates inoculated with 1 ml fluid each.
Backfiltered dialysate as a substitution solution
If the dialysis fluid is ultrapure and the dialyser mem-
brane has the capability of a sterilizing filter, backfiltered
dialysate should in theory become sterile. Under ideal con-
ditions,thisprocedurewouldthereforebemicrobiologically
safe. Although the use of ultrapure dialysis fluid is spread-
ing and the most commonly used high-flux membranes
provide reasonably good protection against a limited quan-
tity of bacterial products, the risk of exposing the blood
to microbiological products should not be underestimated
[53]. Working with ultrapure dialysis fluid and making sure
the respective high-flux membrane has been validated for
endotoxin retention, in addition to limiting the volume of
backfiltered fluid, all contribute to reduce the risk of induc-
ing microinflammation.
Conclusion
In HDF, the fluid serves the purpose of dialysis fluid as
well as substitution solution and the volumes required for
efficient therapy are the largest among blood purification
therapies. This places high and stringent demands on the
chemicalaswellasthemicrobiologicalqualityofthefluids.
The preparation of high-quality fluids for dialysis, starting
with tap water and finishing with ultrapure dialysis fluid or
sterile substitution solution, should be viewed as an inte-
gratedprocesswhereeachstepinthechainfulfilsadefined
objective and is validated for this purpose (Figure 4). No
step should be omitted, and each step must have a wide
margin of operation to give maximum safety. The valida-
tion and quality assurance of all fluid preparation need to
be considered in the light of the risk of exposing patient
blood to bacterial products.
The large volumes of substitution fluid required for op-
timal HDF therapy necessitate the use of on-line prepared
fluid, from a quality perspective as well as practically and
economically. With access to ultrapure dialysis fluid, on-
line preparation of sterile and non-pyrogenic fluid can be
realized by one additional step of controlled ultrafiltra-
tion.Theattentionpresentlyattachedtothemicrobiological
quality of dialysis fluid has led to an increasing number of
clinicsnowoperatingwithultrapuredialysisfluid.Thus,the
clinical benefits of high volume HDF are within reach for
an increasing number of patients who are already dialysed
with high-flux membranes and ultrapure dialysis fluid.Haemodiafiltration 15
Conclusion: Haemodiafiltration-optimal
efficiency and safety
To achieve significant removal of uraemic solutes in the
middle and large molecular weight range, it is not suffi-
cient to use a high-flux membrane in HD; we also need
to add considerable amounts of convection by performing
high volume HDF. Large convective volumes require large
ultrafiltrationvolumes,whichinturnrequirelargevolumes
of high-quality substitution solution. On-line preparation
of the substitution solution as an integral component of
the treatment has eliminated the therapeutic as well as the
practicalandeconomicdrawbacksofclassicalHDFandad-
ditionally brought the therapy to a safety level that exceeds
anyalternativeformofHDF.On-lineHDFhasthepotential
to provide the largest dose of blood purification over the
widest molecular weight range among blood purification
therapies.
When HDF was first conceptualized, it was seen as a
combination of the best of both HD and HF, i.e. a therapy
providing high removal rates of small as well as medium-
sized and large solutes [24]. However, considering the large
number of variables of a HDF treatment and the technol-
ogy available to us today, it is possible to manipulate the
conditions beyond the original objective and miss some of
the potential benefits. It is therefore important that users
of HDF identify the most important outcome parameter for
their patients and adjust the prescription accordingly. The
targetmaybetoreachanadequatedoseofdialysisinalarge
patient, a hypercatabolic patient or in a patient with limited
blood flow capacity. It may also be to provide extended re-
moval of large solutes or it may just be to provide the most
biocompatible and effective dialysis treatment available to
us today—haemodiafiltration [54].
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